LLY Stock Alert: What to Know as Eli Lilly Teams Up With CVS on Weight-Loss Drugs

Eli Lilly (LLY) stock extended gains on Wednesday after the pharmaceutical behemoth announced a new direct-to-consumer (DTC) collaboration with CVS Health (CVS).

The press release said this team-up aims to improve patient access, affordability, and pharmacy support for Eli Lilly's blockbuster weight-loss treatments, Zepbound and Foundayo.

Jeff Bezos Says He's Selling $1 Billion In Amazon Stock Every Year to Fund Blue Origin — 'It's The Most Important Work I'm Doing'

Apple's New CEO Is Bringing a Familiar Face Back From Retirement. The Shift Is Happening.

Here's a Realistic Roadmap Toward Generating $1,000 a Month in Options Trading Income

Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else.

At the time of writing, Eli Lilly shares are up more than 35% versus their April low.

Under the expanded partnership, CVS has agreed to integrate Lilly's weight-loss therapies into its connected care network.